{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:23:22Z","timestamp":1787772202282,"version":"build-2784847793"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7]]},"abstract":"\n Objectives:<\/jats:title>\n Androgenetic alopecia (AGA) is the most common cause of hair loss in men and women, affecting about 30% of men and 15% of women at 30 years and 80% and 48% at 70 years, respectively. This study aims to assess the effectiveness of growth factor cocktail therapy including fibroblast growth factor 9 (FGF9) (Cellcurin) in men and women with AGA.<\/jats:p>\n <\/jats:sec>\n \n Materials and Methods:<\/jats:title>\n \n This is a single-center randomized controlled trial, conducted with 10 men and 10 women with AGA. Eight men participated in the therapeutic group and two men in the control group. Eight women participated in the therapeutic group and two women in the control group. All were classified by sex, age, duration, and degrees of progression of AGA. The study obtained approval from the Research Ethics Committee (REC) of the Federal University of Uberlandia at approval number: 36918620.8.0000.5152. Six microneedling sessions were performed with an electromedical pen with an interval of 15 days between sessions. In the therapeutic group, sterile injectable Cellcurin was used and, in the control group, injectable sterile minoxidil 5 mg\/ml 2 ml, both through the drug delivery system. Trichoscopic photos were taken before and after 12 weeks in the frontal and vertex regions. Descriptive statistics were performed using the\n t<\/jats:italic>\n -test with the IBM SPSS-25 software.\n <\/jats:p>\n <\/jats:sec>\n \n Results:<\/jats:title>\n \n Men and women showed an expressive and significant increase in the amount of hair per cm\n 2<\/jats:sup>\n after Cellcurin therapy, as well as an increase in the amount of terminal hair, vellus hair, sum of the terminal hair diameters, and mean of the terminal hair diameters in both regions, frontal and vertex.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions:<\/jats:title>\n \n In this study, we demonstrated that the use of Cellcurin in the treatment of AGA in men and women is associated with an increase in the amount of hair per cm\n 2<\/jats:sup>\n , in the amount of terminal hair per cm\n 2<\/jats:sup>\n , in the amount of vellus hair per cm\n 2<\/jats:sup>\n , in the number obtained by the sum of the terminal hair diameters per cm\n 2<\/jats:sup>\n , as well as an increase in the mean diameter of the terminal hairs.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.4103\/ijt.ijt_39_21","type":"journal-article","created":{"date-parts":[[2024,4,12]],"date-time":"2024-04-12T06:00:09Z","timestamp":1712901609000},"page":"133-143","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Growth Factor Cocktail Including Fibroblast Growth Factor 9 (Cellcurin) in the Treatment of Androgenetic Alopecia in Men and Women: A Randomized Controlled Trial"],"prefix":"10.4103","volume":"15","author":[{"given":"Leonardo de Medeiros","family":"Quirino","sequence":"first","affiliation":[{"name":"Medicine Faculty, Federal University of Uberlandia, Uberl\u00e2ndia, Brazil"},{"name":"BWS Faculty Sao Paulo, University Center of Patos de Minas, Patos de Minas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovana Vilela","family":"Rocha","sequence":"additional","affiliation":[{"name":"Medical School, University Center of Patos de Minas, Patos de Minas, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,4,5]]},"reference":[{"key":"R1-20240903","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1111\/j.1749-6632.1951.tb31971.x","article-title":"Patterned loss of hair in man: Types and incidence","volume":"53","author":"Hamilton","year":"1951","journal-title":"Ann NY Acad Sci"},{"key":"R2-20240903","doi-asserted-by":"crossref","first-page":"542","DOI":"10.3892\/etm.2013.1126","article-title":"Quality of life in women with female pattern hair loss and the impact of topical minoxidil treatment on quality of life in these patients","volume":"6","author":"Zhuang","year":"2013","journal-title":"Exp Ther Med"},{"issue":"Suppl 6","key":"R3-20240903","first-page":"S1","article-title":"Evidence-based (S3) Guideline for the treatment of androgenetic alopecia in women and in men","volume":"9","author":"Blumeyer","year":"2011","journal-title":"J Dtsch Dermatol Ges"},{"key":"R4-20240903","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1111\/j.1087-0024.2005.10102.x","article-title":"Prevalence of male and female pattern hair loss in Maryborough","volume":"10","author":"Gan","year":"2005","journal-title":"J Investig Dermatol Symp Proc"},{"key":"R5-20240903","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1517\/14728222.2014.922956","article-title":"Potential targets in the discovery of new hair growth promoters for androgenic alopecia","volume":"18","author":"Jain","year":"2014","journal-title":"Expert Opin Ther Targets"},{"key":"R6-20240903","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/exd.12965","article-title":"Hunting the genes in male-pattern alopecia: How important are they, how close are we and what will they tell us?","volume":"25","author":"Heilmann-Heimbach","year":"2016","journal-title":"Exp Dermatol"},{"key":"R7-20240903","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/exd.12339","article-title":"Insulin-like growth factor-1: Roles in androgenetic alopecia","volume":"23","author":"Panchaprateep","year":"2014","journal-title":"Exp Dermatol"},{"key":"R8-20240903","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1517\/13543784.2013.784743","article-title":"New investigational drugs for androgenetic alopecia","volume":"22","author":"Valente","year":"2013","journal-title":"Expert Opin Investig Drugs"},{"key":"R9-20240903","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1111\/dth.12390","article-title":"Multi-therapies in androgenetic alopecia: Review and clinical experiences","volume":"29","author":"Rossi","year":"2016","journal-title":"Dermatol Ther"},{"key":"R10-20240903","doi-asserted-by":"crossref","first-page":"16","DOI":"10.4172\/2155-9554-C5-079","article-title":"Experience of growth factor cocktail treatment in the patients with Androgenetic Alopecia (AGA)","volume":"9","author":"Ro","year":"2018","journal-title":"J Clin Exp Dermatol Res"},{"key":"R11-20240903","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1111\/j.1346-8138.2012.01680.x","article-title":"Effects of topical application of growth factors followed by microneedle therapy in women with female pattern hair loss: A pilot study","volume":"40","author":"Lee","year":"2013","journal-title":"J Dermatol"},{"key":"R12-20240903","first-page":"184","article-title":"Therapeutic effects of growth factor cocktail treatment in patients with androgenetic alopecia according to the depth of microneedle","volume":"54","author":"Ro","year":"2016","journal-title":"Korean J Dermatol"},{"key":"R13-20240903","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1038\/nm.3181","article-title":"Fgf9 from dermal \u03b3\u03b4 T cells induces hair follicle neogenesis after wounding","volume":"19","author":"Gay","year":"2013","journal-title":"Nat Med"},{"key":"R14-20240903","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1346-8138.1998.tb02507.x","article-title":"Principles of hair cycle control","volume":"25","author":"Paus","year":"1998","journal-title":"J Dermatol"},{"key":"R15-20240903","doi-asserted-by":"crossref","first-page":"1647","DOI":"10.3390\/ijms15011647","article-title":"Signaling involved in hair follicle morphogenesis and development","volume":"15","author":"Rishikaysh","year":"2014","journal-title":"Int J Mol Sci"},{"key":"R16-20240903","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/DSS.0000000000000924","article-title":"Microneedling","volume":"43","author":"Hou","year":"2017","journal-title":"Dermatol Surg"},{"key":"R17-20240903","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/jdv.14624","article-title":"Evidence-based (S3) guideline for the treatment of androgenetic alopecia in women and in men \u2013 Short version","volume":"32","author":"Kanti","year":"2018","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"R18-20240903","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s40257-014-0077-5","article-title":"Androgenetic alopecia: An evidence-based treatment update","volume":"15","author":"Varothai","year":"2014","journal-title":"Am J Clin Dermatol"}],"container-title":["International Journal of Trichology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_39_21","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T18:31:32Z","timestamp":1787769092000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ijt.ijt_39_21"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.4103\/ijt.ijt_39_21","relation":{},"ISSN":["0974-7753","0974-9241"],"issn-type":[{"value":"0974-7753","type":"print"},{"value":"0974-9241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"2021-04-13","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-06-14","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}